Last reviewed · How we verify
NCT03776305
Imipenem in Critically Ill Patients
Phase 4 trial testing Imipenem in Critically Ill Patients With ECMO in 12 participants. Status unknown.
1 February 2018
Quick facts
| Lead sponsor | Prince of Songkla University |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 1 December 2015 |
| Primary completion | 1 February 2018 |
| Estimated completion | 30 December 2020 |
| Sites | 1 location across Thailand |
Drugs / interventions tested
- Imipenem (IMIPENEM) — full drug profile →
Conditions studied
- Critically Ill Patients With ECMO — all drugs for Critically Ill Patients With ECMO →
Sponsor
Prince of Songkla University
Who can join
Adults 18 to 90, any sex, with Critically Ill Patients With ECMO. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Extracorporeal membrane oxygenation (ECMO) has become increasingly used for lifesaving respiratory and/or cardiac failure support in critically ill patients, including those with life-threatening severe infections. This cardiopulmonary bypass device has been shown to enhance the profound pathophysiological changes in this patient population, resulting in an alteration of the pharmacokinetics (PK) of antimicrobial agents. The aim of this study was to determine the effect of ECMO on the PK of imipenem in critically ill patients supported by this cardiopulmonary bypass device. Methods The study was conducted in critically ill patients with respiratory and/or cardiac failure and suspected severe nosocomial infections who were supported by ECMO. All patients received a 1-h infusion of 0.5 g of imipenem every 6 h and imipenem PK studies were carried out on the fourth dose of drug administration.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Pharmacokinetics and Monte Carlo Dosing Simulations of Imipenem in Critically Ill Patients with Life-Threatening Severe Infections During Support with Extracorporeal Membrane Oxygenation.
Jaruratanasirikul S, Vattanavanit V, Wongpoowarak W, Nawakitrangsan M, et al · · 2020 · cited 8× · PMID 32886347 · DOI 10.1007/s13318-020-00643-3
Verify or expand the search:
- PubMed search for NCT03776305
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Imipenem
Trials testing the same drug.
- NCT04310930 — Finding the Optimal Regimen for Mycobacterium Abscessus Treatment · Phase 2, PHASE3 · recruiting
- NCT04208763 — A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Man · NA · unknown
- NCT03733340 — Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT · Phase 2, PHASE3 · unknown
- NCT03858387 — PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients · unknown
- NCT03308214 — The Analysis of Factors Influencing the Vd of Imipenem in Septic Shock Patients · completed
Other Prince of Songkla University trials
Trials by the same sponsor.
- NCT06841133 — Chinese Art Activities or Combined With Peer Group Participation on Psychological Well Being · NA · not yet recruiting
- NCT06837116 — Immunogenicity of an Intradermal Qdenga Vaccine Among Healthy Volunteers · EARLY_PHASE1 · completed
- NCT06476652 — Effect of Simple Simulator-based Training on Initial Performance of Novices Iultrasound-guided Adductor Canal Block · enrolling by invitation
- NCT07245966 — Pharmacokinetics and Pharmacodynamics of High Dose Ceftriaxone in Patients With Sepsis · completed
- NCT06265870 — Specific Versus Empirical Anthelminthic Treatment in Eosinophilia · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03776305 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Prince of Songkla University
- Last refreshed: 15 February 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03776305.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing